Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ML261 in Relapsed/Refractory Small Cell Lung Cancer or Select Neuroendocrine Carcinomas
NCT07488923Phase 1Recruiting
- Start
- Jun 2026
- Primary completion
- Mar 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ML261 in small cell lung cancer (SCLC), extrapulmonary neuroendocrine carcinoma (EPNEC), gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC) and 1 more. Primary endpoint: Dose-Limiting Toxicities at 28 days. Started Jun 2026; status: recruiting.
02
Drugs
ML261
03
Conditions
small cell lung cancer (SCLC)extrapulmonary neuroendocrine carcinoma (EPNEC)gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC)neuroendocrine prostate cancer (NEPC)
Beyond the preview
Go deeper on NCT07488923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07488923.